Glucagon-like Peptide-1 (GLP-1) Agonists for 7MM: Market Size, Target Population, Competitive Landscape & Forecasts, 2020-2023 and 2024-2034
March 04, 2024 11:24 ET
|
Research and Markets
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ...
Global Glucagon-Like Peptide 1 (GLP-1) Agonist (Tirzepatide, Semaglutide, Dulaglutide, Others) Market Research Report 2024
February 26, 2024 11:24 ET
|
Research and Markets
Dublin, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type, End-Use (Type 2 Diabetes, NASH, Obesity), By Distribution...
Global Glucagon-like Peptide 1 (GLP-1) Market Soars to $18.75 Billion by 2023, Fueled by Increasing Healthcare Expenditure and Aging Population
November 10, 2023 08:48 ET
|
Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Glucagon-like Peptide 1 (GLP-1) Market (by Product, Route of Administration, & Region): Insights and Forecast with Potential Impact of...
Continuous Development of GLP-1 Agonists Drives Dominance in the Diabetes Drug Market
August 11, 2023 07:58 ET
|
Research and Markets
Dublin, Aug. 11, 2023 (GLOBE NEWSWIRE) -- The "Diabetes Drugs Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been...
Global Glucagon-like Peptide 1 (GLP-1) Market Analysis Report 2023: Potential Clinical Application of GLP-1 Receptor Agonists For the Treatment of NASH Gaining Momentum
January 30, 2023 06:23 ET
|
Research and Markets
Dublin, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The "Global Glucagon-like Peptide 1 (GLP-1) Market: Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products), By Route of...
Diabetic Nephropathy Disease Analysis Report 2021: Overall Likelihood of Approval of a Phase I DN Asset is 4%, and the Average Probability a Drug Advances from Phase III is 33.3%
March 23, 2021 08:13 ET
|
Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Diabetic Nephropathy" report has been added to ResearchAndMarkets.com's offering. Diabetic nephropathy, also known as diabetic...